Petros Christopoulos

Research interests

Publications

• Interferon-stimulated neutrophils as a predictor of immunotherapy response

  Cancer Cell · 2024 · 10.1016/j.ccell.2023.12.005

• Tumour mutational burden: clinical utility, challenges and emerging improvements

  Nature Reviews Clinical Oncology · 2024 · 10.1038/s41571-024-00932-9

• Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

  Cancer Discovery · 2023 · 10.1158/2159-8290.cd-22-1420

• Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

  Frontiers in Oncology · 2021 · 10.3389/fonc.2021.703893

• Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

  Journal of Thoracic Oncology · 2021 · 10.1016/j.jtho.2021.06.025

• Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

  ESMO Open · 2021 · 10.1016/j.esmoop.2021.100254

• Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

  International Journal of Molecular Sciences · 2021 · 10.3390/ijms22115632

• A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma

  OncoImmunology · 2021 · 10.1080/2162402x.2020.1860586

• Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

  Cancers · 2020 · 10.3390/cancers12041046

• Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer

  Cancers · 2020 · 10.3390/cancers12061604

• Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

  Lung Cancer · 2020 · 10.1016/j.lungcan.2020.10.006

• Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

  Lung Cancer · 2020 · 10.1016/j.lungcan.2020.10.012

• Variant classification in precision oncology

  International Journal of Cancer · 2019 · 10.1002/ijc.32358

• FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC

  Cancers · 2019 · 10.3390/cancers11050652

• Optimizing panel-based tumor mutational burden (TMB) measurement

  Annals of Oncology · 2019 · 10.1093/annonc/mdz205

• Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

  International Journal of Cancer · 2019 · 10.1002/ijc.32133

• Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts

  Journal of Thoracic Oncology · 2019 · 10.1016/j.jtho.2019.07.006

• Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians

  Translational Lung Cancer Research · 2018 · https://doi.org/10.21037/tlcr.2018.08.14

• Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis

  International Journal of Cancer · 2018 · 10.1002/ijc.31878

• EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non‐small cell lung cancer

  International Journal of Cancer · 2018 · 10.1002/ijc.31275

• Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma

  International Journal of Cancer · 2018 · 10.1002/ijc.31893

• Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

  OncoImmunology · 2018 · 10.1080/2162402x.2018.1526613

• AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients

  International Journal of Oncology · 2017 · 10.3892/ijo.2017.3834

• Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

  Annals of Oncology · 2017 · 10.1093/annonc/mdx268

• Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL

  Blood · 2011 · 10.1182/blood-2010-07-299321

Current projects

No projects listed.